Oragenics, Inc. is advancing its brain-first recovery platform towards clinical milestones with intranasal therapeutics for concussion. The company’s proprietary nasal delivery technology aims to transform neurotrauma care with lead candidate ONP-002. Oragenics has achieved key clinical milestones, including securing HREC approval in Australia and finalizing a manufacturing agreement. They anticipate Phase IIa trials to launch in Q3 2025, positioning them as leaders in intranasal neurotrauma therapeutics. The company’s focus on concussion treatment may extend to other neurological conditions, leveraging a projected $40 billion nasal drug delivery market opportunity by 2030.

Oragenics recently raised $16.5 million to accelerate ONP-002 clinical development and advance their nasal delivery platform. The company’s strategic partnerships and engagements in the industry position them to lead in concussion care. With upcoming catalysts like Phase IIa trial initiation in Q3 2025 and an IND submission for Phase IIb trials, Oragenics aims to revolutionize brain injury treatment and improve patient outcomes. Their focus on clinical excellence, platform leadership, and operational discipline drive their mission to pioneer brain-first recovery solutions in neurotrauma care.

Read more at GlobeNewswire: Oragenics Q2 2025 Shareholder Update